Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Other Accumulated Expenses for 7 consecutive years, with $258000.0 as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 44.28% to $258000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $258000.0 through Dec 2025, down 44.28% year-over-year, with the annual reading at $258000.0 for FY2025, 44.28% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $258000.0 at Fulcrum Therapeutics, up from $236000.0 in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $463000.0 in Q4 2024, with the low at $9000.0 in Q1 2023.
  • Average Other Accumulated Expenses over 5 years is $191100.0, with a median of $153500.0 recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses tumbled 93.28% in 2023, then skyrocketed 4177.78% in 2024.
  • Over 5 years, Other Accumulated Expenses stood at $74000.0 in 2021, then surged by 41.89% to $105000.0 in 2022, then skyrocketed by 277.14% to $396000.0 in 2023, then rose by 16.92% to $463000.0 in 2024, then plummeted by 44.28% to $258000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $258000.0, $236000.0, and $173000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.